Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

References

• American Lung AssociationLung cancer fact sheet Available from: http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/lung-cancer/learn-about-lung-cancer/lung-cancer-fact-sheet.htmlAccessed March 5, 2016
   Google Scholar
• Paz-AresLde MarinisFDediuMMaintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLancet Oncol201213324725522341744
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• LindemanNICaglePTBeasleyMBMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyArch Pathol Lab Med2013137682886023551194
   PubMed Web of Science ®Google Scholar
• HerzbergBCampoMJGainorJFImmune checkpoint inhibitors in non-small cell lung cancerOncologist2016211826712959
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• GiacconeGThe potential of antiangiogenic therapy in non-small cell lung cancerClin Cancer Res2007131961197017404076
   PubMed Web of Science ®Google Scholar
• FerraraNPathways mediating VEGF-independent tumor angiogenesisCytokine Growth Factor Rev2010211212620005148
   PubMed Web of Science ®Google Scholar
• FolkmanJAngiogenesis: an organizing principle for drug discovery?Nat Rev Drug Discov20076427328617396134
   PubMed Web of Science ®Google Scholar
• AlevizakosMKaltsasSSyrigosKNThe VEGF pathway in lung cancerCancer Chemother Pharmacol20137261169118124085262
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic targetNature2005438707096797416355214
   PubMed Web of Science ®Google Scholar
• SpratlinJCohenREadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol201028578078720048182
   PubMed Web of Science ®Google Scholar
• CalvettiLPilottoSCarbogninLThe coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectivesExpert Opin Biol Ther20151591359137026190526
   PubMed Web of Science ®Google Scholar
• CamidgeDRBergeEMDoebeleRCA phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerJ Thorac Oncol20149101532153925170639
   PubMed Web of Science ®Google Scholar
• DoebeleRCSpigelDTehfeMPhase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancerCancer2015121688389225377507
   PubMed Web of Science ®Google Scholar
• GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• SpratlinJCohenREadensMPhase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2J Clin Oncol201028578078720048182
   PubMed Web of Science ®Google Scholar
• WadhwaRTaketaTSudoKRamucirumab: a novel antiangiogenic agentFuture Oncol20139678979523718298
   PubMed Web of Science ®Google Scholar
• SpratlinJLMulderKEMackeyJRRamucirumab (IMC-1121B): a novel attack on angiogenesisFuture Oncol2010671085109420624120
   PubMed Web of Science ®Google Scholar
• FranklinMCNavarroECWangYThe structural basis for the function of two anti-VEGF receptor 2 antibodiesStructure20111981097110721827946
   PubMed Web of Science ®Google Scholar
• MiaoHQHuKJimenezXPotent neutralization of VEGF biological activities with a fully human antibody fab fragment directed against VEGF receptor 2Biochem Biophys Res Commun2006345143844516682007
   PubMed Web of Science ®Google Scholar
• ChioreanEGHurwitzHICohenRBPhase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumorsAnn Oncol20152661230123725787923
   PubMed Web of Science ®Google Scholar
• Cyramza (ramucirumab) [package insert]Indianapolis, INEli Lilly and Company2015
   Google Scholar
• YohKHosomiYKasaharaKA randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapyLung Cancer20169918619327565938
   PubMed Web of Science ®Google Scholar
• ReckMKaiserRMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387151540155026712084
   PubMed Web of Science ®Google Scholar
• TianRYanHZhangFIncidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysisOncotarget2016740661826619127507055
   PubMedGoogle Scholar
• QiWXFuSZhangQGuoXMIncidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysisJ Cancer Res Ther201612277578127461650
   PubMed Web of Science ®Google Scholar
• WangZZhangJZhangLRisk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trialsJ Chemother201628432833426099278
   PubMed Web of Science ®Google Scholar
• PérolMCiuleanuTEArrietaOQuality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyLung Cancer2016939510326898621
   PubMed Web of Science ®Google Scholar
• GaronEBReckMPaz-AresLTreatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-small-cell lung cancerClin Lung Cancer2017181969927894601
   PubMed Web of Science ®Google Scholar
• ManegoldCDingemansACGrayJEThe potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLCJ Thorac Oncol201712219420727729297
   PubMed Web of Science ®Google Scholar
• HerbstRSBendellJCIsambertNA phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, nonsmall cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a resultsJ Clin Oncol201634Suppl abstr3056
   Web of Science ®Google Scholar